RxDoctor Payments Data

Yana Rodriguez, PA

Medical · New Hyde Park, NYNPI 1174800056

Payments from drug & device makers

$1,367in general payments, 2019–2025

Across 65 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$243
  • Novartis$238
  • Boston Scientific$177
  • E.r. Squibb & Sons, L.L.C.$139
  • Amgen$104
  • Novo Nordisk$104
  • plus $363 from 10 others

What the payments were for

  • Food & beverage$1,367100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,367 in reported general payments places this provider in the 70th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$60,961
Medicare patients
375
Services billed
1,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$54,923
OzempicSemaglutide31$38,414
XareltoRivaroxaban29$26,773
JardianceEmpagliflozin13$18,273
TradjentaLinagliptin20$10,407
PradaxaDabigatran Etexilate Mesylate15$5,439
Metoprolol Succinate147$2,559
Celecoxib25$1,966
Ezetimibe52$1,778
Atorvastatin Calcium167$1,538
Rosuvastatin Calcium72$1,479
SynthroidLevothyroxine Sodium20$1,341
Midodrine Hcl13$1,152
Losartan Potassium108$1,076
Amlodipine Besylate166$1,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$243$54,92370 claims
Novo NordiskOzempic$104$38,41431 claims
Boehringer IngelheimJardiance, Tradjenta, Pradaxa$53$34,11948 claims
Johnson & JohnsonXarelto$68$26,77329 claims
AbbVieSynthroid$55$1,34120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,395 medical providers in New York.

Other medical in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →